Navigation Links
BELLUS Health reports results for first quarter of fiscal 2009
Date:5/6/2009

LAVAL, QC, May 6 /PRNewswire-FirstCall/ - BELLUS Health Inc. ("BELLUS Health" or the "Company") (TSX: BLU) reported results for the first quarter ended March 31, 2009. The Company reported a net loss of $9,907,000 ($0.20 per share) for the quarter, compared to $13,042,000 ($0.27 per share) for the same period the previous year. The decrease in the net loss is mainly due to a reduction in research and development (R&D) expenses, before research tax credits and grants, which amounted to $3,610,000 for the current quarter, compared to $8,780,000 for the same period the previous year. The decrease is mainly attributable to a reduction in the research and development of tramiprosate (ALZHEMED(TM); homotaurine) for the treatment of Alzheimer's disease following the Company's decision in November 2007 to terminate the tramiprosate (ALZHEMED(TM)) pharmaceutical drug development program. The Company is also developing NC-503 (eprodisate) for the treatment of Type II diabetes and certain features of metabolic syndrome.

As at March 31, 2009, the Company had available cash, cash equivalents and marketable securities of $3,187,000, compared to $10,595,000 at December 31, 2008. The decrease is primarily due to funds used in operating activities.

On April 16, after the end of the first quarter of 2009, the Company announced the completion of the first tranche of its previously announced $20.5 million CAD convertible notes (see Liquidity and capital resources section for further details). BELLUS Health received gross proceeds of $10 million CAD for the issuance of new convertible notes. A second tranche of $10.5 million CAD is expected to be funded by June 2009. In March 2009, the Company announced a reduction in the workforce and other related measures which are expected to result in annual savings of approximately $3.5 million CAD, and the restructuring of the lease of the Company's main premises and the 2006 and 2007 convertible notes, which are expect
'/>"/>

SOURCE BELLUS HEALTH INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine news :

1. BELLUS announces Chief Financial Officer to depart effective May 22, 2009
2. BELLUS Health inc. announces completion of first tranche of financing
3. BELLUS Health reports results for the fourth quarter of 2008
4. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BELLUS Health Inc.
5. BELLUS Health announces formal notice to voluntarily delist from NASDAQ
6. BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market
7. BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
8. BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update
9. BELLUS Health to present at the Rodman and Renshaw 10th Annual Healthcare Conference
10. BELLUS Health provides update on activities
11. BELLUS Health announces closing of Innodia acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... Virginia entrepreneur ... is still strongly maintaining her firm’s success in the hair care and distribution ... upcoming city-to-city tour, Ellis will be providing “Look and learn” live demonstrations, as ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... ranked a top-five hospital by U.S. News & World Report, to provide breaking ... , Editorial and marketing groups within OncLive, which provides oncologists resources and ...
(Date:9/1/2015)... ... 01, 2015 , ... The Jerry Segal Classic to benefit the patients of ... Country Club in Lafayette Hill, PA. Over the past 26 years, the Classic, organized ... and services designed to support patients and their families during their time at Magee ...
(Date:9/1/2015)... , ... September 01, 2015 , ... With former IBMers ... and Math) disciplines since its inception more than 35 years ago. A pilot program ... and their teachers - and, not just those intent on pursuing careers in these ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... announced the release of version 5.2 of the FirstSpirit Content Management System with ... initiative. With the new version of FirstSpirit, companies will be well on their ...
Breaking Medicine News(10 mins):Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3
... By Amanda Gardner HealthDay Reporter , TUESDAY, Jan. ... moved to rescind approval of the drug Avastin to treat ... anti-cancer medication ups the odds of congestive heart failure in ... the Journal of Clinical Oncology , included almost 4,000 ...
... Researchers have produced a lasting anti-cocaine immunity in mice by ... cold virus with a particle that mimics cocaine. , ... the online edition of Molecular Therapy and funded by ... strategy might be the first to offer cocaine addicts a fairly ...
... -- Elderly people who lose their teeth may be at ... study included more than 4,000 Japanese participants, 65 and older, ... with participants who still had many of their natural teeth, ... to have experienced some memory loss or have early-stage Alzheimer,s ...
... cortical nerve cells or neurons reside in the brain,s gray ... matter, but some people with schizophrenia have a higher number ... arise in schizophrenia as a consequence of both genetic and ... has now been studied in detail in a paper by ...
... , New Rochelle, NY, January 4, 2011Lowering the body ... severe brain injury may reduce neurologic complications and improve ... injury (TBI) has been demonstrated in national studies. According ... field, when and how it is administered should depend ...
... TUCSON, Ariz. (January 4, 2011) -- Cumbersome glaucoma tests ... history thanks to a home test developed by an ... hand-held instrument involving a system of micro-force sensors, specially ... by researchers at the UA College of Engineering. The ...
Cached Medicine News:Health News:More Evidence Links Avastin to Heart Failure in Breast Cancer Patients 2Health News:More Evidence Links Avastin to Heart Failure in Breast Cancer Patients 3Health News:Vaccine blocks cocaine high in mice 2Health News:Vaccine blocks cocaine high in mice 3Health News:Neuronal migration errors: Right cells, wrong place 2Health News:Optimizing patient outcomes after therapeutic hypothermia for traumatic brain injury 2Health News:New glaucoma test allows earlier, more accurate detection 2
(Date:9/1/2015)... , September 1, 2015 ... on the basis of sectors, products & services ... globally coupled with the increasing demand of advanced ... expected to propel the growth for bioinformatics market. ... information efficiently is known as bioinformatics. Decreasing cost ...
(Date:9/1/2015)... , Aug. 31, 2015 Research and ... the "Regulatory Affairs for Support Staff (London, UK ... This two day course provides an ... drug development and has been designed specifically for those ... You will gain an overview of EU regulatory procedures ...
(Date:9/1/2015)... LONDON , September 1, 2015 - ... of GARFIELD-AF R egistry data presented ... real-world insights on the evolution of ... -   The first-ever two-year ... showcased at ESC Congress 2015 expose that all-cause death was the most frequent ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Regulatory Affairs for Support Staff Seminar (London, UK - September 24-25, 2015) 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9
... the newest and most advanced automated immunoassay ... AIA-1800 launches with a full menu of ... reproductive, cardiac, and anemia assays. ,The AIA-1800 ... primary tube sampling, auto dilution, auto pretreatment, ...
EZ-PSA is a one-step immunoassay for the rapid, qualitative determination of human Prostate Specific Antigen (PSA) in whole blood. The test is intended for professional use as an aid in the diagnosis...
... name from its first known site of ... of PSA circulates bound to anti-chymotrypsin (PSA-ACT) ... PSA are elevated in patients with prostate ... [1-3]. In addition, PSA serum levels appear ...
... Functional Vision, Quality of Vision and ... both target illumination and glare luminance ... results. Day/Night testing with/without glare and ... and all ANSI standards. All Light ...
Medicine Products: